Last updated on May 2018

A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma


Brief description of study

The purpose of this study is to compare the efficacy and safety of PEGylated Recombinant Human Hyaluronidase (PEGPH20) combined with nab-paclitaxel plus gemcitabine (PAG treatment), compared with placebo combined with nab-paclitaxel plus gemcitabine (AG treatment), in participants with hyaluronan (HA)-high Stage IV previously untreated pancreatic ductal adenocarcinoma (PDA). Participants will be randomized in a 2:1 ratio to PAG or AG treatment.

Clinical Study Identifier: NCT02715804

Contact Investigators or Research Sites near you

Start Over

Halozyme Study Information

H pital Beaujon
Clichy Cedex, France
  Connect »

Halozyme Study Information

Institut Mutualiste Montsouris
Paris, France
3.95miles
  Connect »

Halozyme Study Information

Institut De Cancerologie Gustave Roussy
Villejuif, France
8.11miles
  Connect »